Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Celsion appoints Stacy Lindborg to board of directors » 08:10
06/08/21
06/08
08:10
06/08/21
08:10
CLSN

Celsion

$1.21 /

-0.02 (-1.63%)

, BCLI

BrainStorm

$3.94 /

+0.31 (+8.54%)

Celsion (CLSN) announced…

Celsion (CLSN) announced the appointment of Stacy Lindborg, Ph.D. to its Board of Directors, effective June 4, 2021. Lindborg's appointment fills the vacancy created by Alberto Martinez upon his retirement from Celsion's Board on December 31, 2020. Dr. Lindborg brings to Celsion more than 25 years of pharmaceutical industry experience. Lindborg's holds the position of Executive Vice President and Global Head of Clinical Research at Brainstorm Cell Therapeutics (BCLI).

ShowHide Related Items >><<
CLSN Celsion
$1.21 /

-0.02 (-1.63%)

BCLI BrainStorm
$3.94 /

+0.31 (+8.54%)

CLSN Celsion
$1.21 /

-0.02 (-1.63%)

07/16/20 Oppenheimer
Celsion downgraded to Perform at Oppenheimer
07/16/20 Oppenheimer
Celsion downgraded to Perform from Outperform at Oppenheimer
07/14/20 Dawson James
Celsion downgraded to Hold from Buy at Dawson James
BCLI BrainStorm
$3.94 /

+0.31 (+8.54%)

02/05/21 Maxim
BrainStorm upgraded to Buy from Hold at Maxim
02/04/21 Maxim
BrainStorm upgraded to Buy from Hold at Maxim
11/18/20 Maxim
BrainStorm downgraded to Hold from Buy at Maxim
11/17/20 Maxim
BrainStorm downgraded to Hold from Buy at Maxim
CLSN Celsion
$1.21 /

-0.02 (-1.63%)

BCLI BrainStorm
$3.94 /

+0.31 (+8.54%)

CLSN Celsion
$1.21 /

-0.02 (-1.63%)

BCLI BrainStorm
$3.94 /

+0.31 (+8.54%)

Over a week ago
Hot Stocks
Celsion urges shareholders to vote at 2021 Annual Meeting » 08:20
06/02/21
06/02
08:20
06/02/21
08:20
CLSN

Celsion

$1.17 /

-0.02 (-1.69%)

Celsion Corporation…

Celsion Corporation reminded stockholders that the virtual Annual Meeting of Stockholders is scheduled for Friday, June 4, 2021 at 10:00 a.m., Eastern Time and called on stockholders to vote to ensure that a quorum is present to hold the meeting. Stockholders holding common stock at the close of business on April 5, 2021 are entitled to vote at the meeting. Meeting materials, including the definitive proxy statement filed with the Securities and Exchange Commission on April 20, 2021, along with a proxy card, were mailed on April 21, 2021, to stockholders of record as of April 5, 2021 and made available at www.sec.gov. Celsion is also asking stockholders to follow the Board of Directors' recommendation to vote FOR Proposal #3 to increase the number of authorized shares of common stock. Proposal #3 involves an amendment to the Company's Certificate of Incorporation and therefore requires a majority of all shares outstanding to vote FOR this proposal in order for it to pass. ISS and Glass Lewis have both recommended that stockholders vote FOR the Company's proposal to increase the number of authorized shares. There are four proposals to be voted on during the June 4th meeting. Please review the information regarding each of these proposals in their entirety, which can be found in the definitive proxy statement filed with the SEC on April 20, 2021. As stated in the Proxy, Proposal #3 is being presented to increase the number of shares of the Company's common stock authorized for issuance from 112,500,000 to 172,500,000. The Board of Directors believes that the increase in authorized common shares will provide the Company with the ability to support its future anticipated growth and would provide the Company with greater flexibility to consider and respond to future business opportunities and needs as they arise, including stock-based acquisitions of new technology and product development candidates and equity financings. The availability of additional shares of Common Stock would permit the Company to undertake certain of the foregoing actions without delay and expense associated with holding a Special Meeting of Stockholders to obtain stockholder approval each time such an opportunity arises that would require the issuance of shares of our Common Stock

ShowHide Related Items >><<
CLSN Celsion
$1.17 /

-0.02 (-1.69%)

CLSN Celsion
$1.17 /

-0.02 (-1.69%)

07/16/20 Oppenheimer
Celsion downgraded to Perform at Oppenheimer
07/16/20 Oppenheimer
Celsion downgraded to Perform from Outperform at Oppenheimer
07/14/20 Dawson James
Celsion downgraded to Hold from Buy at Dawson James
CLSN Celsion
$1.17 /

-0.02 (-1.69%)

CLSN Celsion
$1.17 /

-0.02 (-1.69%)

Hot Stocks
Celsion urges shareholders to vote at 2021 Annual Meeting » 08:46
05/27/21
05/27
08:46
05/27/21
08:46
CLSN

Celsion

$1.16 /

+0.055 (+4.98%)

Celsion Corporation…

Celsion Corporation reminded stockholders that the virtual Annual Meeting of Stockholders is scheduled for Friday, June 4, 2021 at 10:00 a.m., Eastern Time and called on stockholders to vote to ensure that a quorum is present to hold the meeting. Stockholders holding common stock at the close of business on April 5, 2021 are entitled to vote at the meeting. Meeting materials, including the definitive proxy statement filed with the Securities and Exchange Commission on April 20, 2021, along with a proxy card, were mailed on April 21, 2021, to stockholders of record as of April 5, 2021 and made available at www.sec.gov. Since a majority of all shares outstanding is required, Celsion is specifically asking stockholders to follow the Board of Directors' recommendation to vote FOR Proposal #3 to increase the number of authorized shares of common stock. Proposal #3 involves an amendment to the Company's Certificate of Incorporation and therefore requires a majority of all shares outstanding to vote FOR this proposal in order for it to pass. ISS and Glass Lewis have both recommended that stockholders vote in favor of the Company's proposal to increase the number of authorized shares. There are four proposals to be voted on during the June 4th meeting. As stated in the Proxy, Proposal #3 is being presented to increase the number of shares of the Company's common stock authorized for issuance from 112,500,000 to 172,500,000. The Board of Directors believes that the increase in authorized common shares will provide the Company with the ability to support its future anticipated growth and would provide the Company with greater flexibility to consider and respond to future business opportunities and needs as they arise, including stock-based acquisitions of new technology and product development candidates and equity financings. The availability of additional shares of Common Stock would permit the Company to undertake certain of the foregoing actions without delay and expense associated with holding a Special Meeting of Stockholders to obtain stockholder approval each time such an opportunity arises that would require the issuance of shares of our Common Stock.

ShowHide Related Items >><<
CLSN Celsion
$1.16 /

+0.055 (+4.98%)

CLSN Celsion
$1.16 /

+0.055 (+4.98%)

07/16/20 Oppenheimer
Celsion downgraded to Perform at Oppenheimer
07/16/20 Oppenheimer
Celsion downgraded to Perform from Outperform at Oppenheimer
07/14/20 Dawson James
Celsion downgraded to Hold from Buy at Dawson James
CLSN Celsion
$1.16 /

+0.055 (+4.98%)

CLSN Celsion
$1.16 /

+0.055 (+4.98%)

Hot Stocks
Celsion expects cash to fund operations through 2024 » 08:20
05/14/21
05/14
08:20
05/14/21
08:20
CLSN

Celsion

/

+

The Company had $54.6…

The Company had $54.6 million in cash and cash equivalents, short-term investments and a receivable on the sale of NOLs as of March 31, 2021. Combined with $15 million of gross proceeds received from the sale of equity in a registered direct offering that closed on April 5, 2021 along with future planned sales of the Company's State of New Jersey NOLs, the Company believes it has sufficient capital resources to fund its operations through 2024.

ShowHide Related Items >><<
CLSN Celsion
/

+

CLSN Celsion
/

+

07/16/20 Oppenheimer
Celsion downgraded to Perform at Oppenheimer
07/16/20 Oppenheimer
Celsion downgraded to Perform from Outperform at Oppenheimer
07/14/20 Dawson James
Celsion downgraded to Hold from Buy at Dawson James
CLSN Celsion
/

+

CLSN Celsion
/

+

Earnings
Celsion reports Q1 EPS (9c) vs. (20c) last year » 08:19
05/14/21
05/14
08:19
05/14/21
08:19
CLSN

Celsion

/

+

Reports Q1 revenue…

Reports Q1 revenue $125,000 vs. $125,000 last year. "Celsion entered 2021 with a focus on a novel DNA-based immunotherapy for ovarian cancer and an initiative for next-generation vaccines with the potential to immunize against a broad range of infectious agents, including coronaviruses. Our platform technologies, TheraPlas and PlaCCine, are rich with promise for a pipeline of product candidates that have potential to address difficult and unaddressed diseases. During the first quarter, the Company extended its cash operating runway through 2024 and strengthened our balance sheet with the successful execution of its financing strategy by raising more than $58 million in gross proceeds from two well placed, registered direct offerings, sales under our at-the-market equity facility, warrant exercises and the sale of our New Jersey State NOLs," said Michael Tardugno, Celsion's chairman, president and CEO. "Our Phase I/II OVATION 2 Study is more than 40% enrolled. With 23 clinical sites activated, encouraging trial data to date and the strong commitment of our clinical investigators, we hope to complete enrollment before the end of 2021. Initial data at the 100 mg/m dose cohort appear to be consistent with the directionally impressive results reported from our Phase Ib dose-escalating OVATION I Study in ovarian cancer. In the OVATION 2 study of 28 patients who completed interval debulking surgery, 81% of those treated with GEN-1 had an R0 resection, compared with 58% of control patients, a 41% improvement. During the first quarter of 2021, we announced an initiative to focus our considerable DNA plasmid experience and competencies on DNA vaccine development, an approach we believe may represent an advance in nucleic acid immunotherapy. Leveraging our clinical-stage TheraPlas platform, we envision a vaccine characterized by a single-plasmid DNA with multiple coding regions. Celsion's plasmid vectors currently in development are designed to promote multiple antigens that are expressed by a single pathogen in combination with a potent immune modifier such as IL-12. IL-12 is the active ingredient in our GEN-1 product candidate. We are well positioned with a capital structure sufficient to support our planned R&D and clinical programs through transformative milestones. In doing so, we look to create significant value for our shareholders, patients and the medical community."

ShowHide Related Items >><<
CLSN Celsion
/

+

CLSN Celsion
/

+

07/16/20 Oppenheimer
Celsion downgraded to Perform at Oppenheimer
07/16/20 Oppenheimer
Celsion downgraded to Perform from Outperform at Oppenheimer
07/14/20 Dawson James
Celsion downgraded to Hold from Buy at Dawson James
CLSN Celsion
/

+

CLSN Celsion
/

+

Over a month ago
Hot Stocks
Celsion receives $1.85M from sale of its New Jersey NOLs » 08:48
05/11/21
05/11
08:48
05/11/21
08:48
CLSN

Celsion

$1.05 /

-0.02 (-1.88%)

Celsion announced it has…

Celsion announced it has received $1.85M in net cash proceeds from the sale of approximately $2M of its unused New Jersey net operating losses, or NOLs. The NOL sales cover the tax years 2018 and 2019 and are administered through the New Jersey Economic Development Authority's Technology Business Tax Certificate Transfer program. This non-dilutive funding, along with more than $58M in gross proceeds from equity offerings completed earlier this year, has significantly strengthened the company's balance sheet. An additional $5M of unused New Jersey NOLs available to the company are planned to be sold and will further increase Celsion's cash position. Based on current budget projections, Celsion notes that this cash balance would be sufficient cash to fund its operations and clinical development programs beyond 2024.

ShowHide Related Items >><<
CLSN Celsion
$1.05 /

-0.02 (-1.88%)

CLSN Celsion
$1.05 /

-0.02 (-1.88%)

07/16/20 Oppenheimer
Celsion downgraded to Perform at Oppenheimer
07/16/20 Oppenheimer
Celsion downgraded to Perform from Outperform at Oppenheimer
07/14/20 Dawson James
Celsion downgraded to Hold from Buy at Dawson James
CLSN Celsion
$1.05 /

-0.02 (-1.88%)

CLSN Celsion
$1.05 /

-0.02 (-1.88%)

Hot Stocks
Celsion announces poster on Phase I/II Ovation 2 study » 08:35
04/01/21
04/01
08:35
04/01/21
08:35
CLSN

Celsion

$1.37 /

-0.255 (-15.69%)

Celsion announced that a…

Celsion announced that a poster highlighting the company's ongoing Phase I/II OVATION 2 study with GEN-1 in advanced ovarian cancer was presented last week at the Virtual Annual Meeting on Women's Cancer, sponsored by the Society of Gynecologic Oncology. The poster was titled "A Phase I/II Study Evaluating Intraperitoneal GEN-1 in Combination with Neoadjuvant Chemotherapy in Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer." GEN-1 is Celsion's DNA-mediated interleukin-12 immunotherapy designed using TheraPlas, its proprietary, synthetic, non-viral nanoparticle delivery system platform. The poster describes the OVATION 2 Study, which combines GEN-1 with standard-of-care neoadjuvant chemotherapy, or NACT, in patients newly diagnosed with Stage III/IV ovarian cancer. NACT is designed to shrink the cancer as much as possible for optimal surgical removal after three cycles of chemotherapy. Following NACT, patients undergo interval debulking surgery, followed by three adjuvant cycles of chemotherapy and up to nine additional weekly GEN-1 treatments, the goal of which is to delay progression and improve overall survival. The Ovation 2 Study is an open-label, 1-to-1 randomized trial, 80% powered to show the equivalent of a 33% improvement in progression-free survival, or PFS, the primary endpoint, when comparing the treatment arm with the control arm. The company recently announced that it has enrolled approximately 40% of the anticipated 110 patients to be enrolled into the Ovation 2 Study. To date, 29 patients have had their interval debulking surgery with the following results: 14 of 17, or 82%, of patients treated with GEN-1 had a R0 resection, which indicates a microscopically margin-negative complete resection in which no gross or microscopic tumor remains in the tumor bed; 7 of 12 patients, or 58%, of patients in the control arm had an R0 resection; this interim data represents a 41% improvement in R0 resection rates for GEN-1- patients compared with control arm patients and is consistent with the reported improvement in resection scores noted in the encouraging Phase I Ovation 1 Study, the manuscript of which has been submitted for publication in a peer-reviewed journal.

ShowHide Related Items >><<
CLSN Celsion
$1.37 /

-0.255 (-15.69%)

CLSN Celsion
$1.37 /

-0.255 (-15.69%)

07/16/20 Oppenheimer
Celsion downgraded to Perform at Oppenheimer
07/16/20 Oppenheimer
Celsion downgraded to Perform from Outperform at Oppenheimer
07/14/20 Dawson James
Celsion downgraded to Hold from Buy at Dawson James
CLSN Celsion
$1.37 /

-0.255 (-15.69%)

CLSN Celsion
$1.37 /

-0.255 (-15.69%)

Syndicate
Celsion raises $15M in a registered direct offering » 08:28
03/31/21
03/31
08:28
03/31/21
08:28
CLSN

Celsion

$1.63 /

+0.045 (+2.85%)

Celsion announced it has…

Celsion announced it has entered into definitive agreements with institutional investors for the purchase and sale of 11,538,462 shares of its common stock at a purchase price of $1.30 per share in a registered direct offering. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering. JonesTrading Institutional Services LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC, are acting as co-placement agents for the offering.

ShowHide Related Items >><<
CLSN Celsion
$1.63 /

+0.045 (+2.85%)

CLSN Celsion
$1.63 /

+0.045 (+2.85%)

07/16/20 Oppenheimer
Celsion downgraded to Perform at Oppenheimer
07/16/20 Oppenheimer
Celsion downgraded to Perform from Outperform at Oppenheimer
07/14/20 Dawson James
Celsion downgraded to Hold from Buy at Dawson James
CLSN Celsion
$1.63 /

+0.045 (+2.85%)

CLSN Celsion
$1.63 /

+0.045 (+2.85%)

Syndicate
Celsion files $100M mixed securities shelf  16:57
03/19/21
03/19
16:57
03/19/21
16:57
CLSN

Celsion

$2.20 /

-0.075 (-3.30%)

 
ShowHide Related Items >><<
CLSN Celsion
$2.20 /

-0.075 (-3.30%)

CLSN Celsion
$2.20 /

-0.075 (-3.30%)

07/16/20 Oppenheimer
Celsion downgraded to Perform at Oppenheimer
07/16/20 Oppenheimer
Celsion downgraded to Perform from Outperform at Oppenheimer
07/14/20 Dawson James
Celsion downgraded to Hold from Buy at Dawson James
CLSN Celsion
$2.20 /

-0.075 (-3.30%)

CLSN Celsion
$2.20 /

-0.075 (-3.30%)

Earnings
Celsion reports 2020 EPS (67c), one est. (73c) » 08:47
03/19/21
03/19
08:47
03/19/21
08:47
CLSN

Celsion

$2.27 /

-0.01 (-0.44%)

Reports revenue $500,000,…

Reports revenue $500,000, one est. $500,000. "Celsion entered 2021 with a renewed focus and prioritization on DNA-based immunotherapies for ovarian cancer and an initiative for next-generation vaccines for preventing or treating infections from a broad range of infectious agents, including coronaviruses, using our PLACCINE DNA vaccine technology platform. All of our work is supported by a strong balance sheet and a three-year cash operating runway," said Michael Tardugno, Celsion's chairman, president and CEO. "Our Phase I/II OVATION 2 Study is over one-third enrolled. With 25 clinical sites to be activated by the end of the first quarter of 2021, encouraging trial data to date and the strong commitment of our clinical investigators, we expect to complete enrollment well before the end of 2021. Initial data at the 100 mg/m dose cohort appear to be consistent with the directionally impressive results reported from our Phase Ib dose-escalating trial in ovarian cancer. Of 28 patients who completed interval debulking surgery, 81% of those treated with GEN-1 had an R0 resection, compared with 58% of control patients, a 41% improvement. During the first quarter of 2021, we announced an initiative to focus our considerable DNA plasmid experience and competencies on DNA vaccine development, an approach we believe may represent an advance in nucleic acid immunotherapy. Leveraging our clinical-stage TheraPlas platform, we envision a vaccine characterized by a single-plasmid DNA with multiple coding regions. Celsion's plasmid vectors that are currently in development are designed to promote multiple antigens that are expressed by a single pathogen in combination with a potent immune modifier such as IL-12. IL-12 is the active ingredient currently used in our product candidate GEN-1. We are well positioned with a capital structure sufficient to support our planned R&D and clinical programs through transformative milestones. In doing so, we look to create significant value for our shareholders, patients and the medical community."

ShowHide Related Items >><<
CLSN Celsion
$2.27 /

-0.01 (-0.44%)

CLSN Celsion
$2.27 /

-0.01 (-0.44%)

07/16/20 Oppenheimer
Celsion downgraded to Perform at Oppenheimer
07/16/20 Oppenheimer
Celsion downgraded to Perform from Outperform at Oppenheimer
07/14/20 Dawson James
Celsion downgraded to Hold from Buy at Dawson James
CLSN Celsion
$2.27 /

-0.01 (-0.44%)

CLSN Celsion
$2.27 /

-0.01 (-0.44%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.